WILSHIRE PHARMS INC
GenericsWILSHIRE PHARMS INC is a generic drug manufacturer focused on Respiratory, Dermatology.
WILSHIRE PHARMS INC's Key Drugs
WILSHIRE PHARMS INC's core commercial portfolio centers on MERZEE, spanning Respiratory and Dermatology — its most strategically important drugs approved in the last 15 years.
WILSHIRE PHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for WILSHIRE PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
WILSHIRE PHARMS INC's Therapeutic Areas
WILSHIRE PHARMS INC's approved drugs and pipeline span 2 therapeutic areas, led by Respiratory and Dermatology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
WILSHIRE PHARMS INC's Top Competitors
WILSHIRE PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Bayer, APOTHECON, and PHARMACIA AND UPJOHN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
WILSHIRE PHARMS INC Pipeline Snapshot
Active clinical trials for WILSHIRE PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MERZEE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2015-12-17
- Latest
- 2025-07-11
- Applications
- 12